Lam Research Stock Rebounds on Analyst Upgrades After Supply Chain Sell-Off

Shares of Lam Research (LRCX) are staging a partial recovery, rising 1.9% in morning trading to $234.54 after a sharp sell-off last week. The rebound is supported by renewed analyst confidence and a broader market rally, even as the stock remains significantly below its recent highs.

Rebound Follows Record Earnings, Guidance Warning

The rally follows a steep decline on October 22, when the stock fell as much as 9% despite the company reporting record quarterly results. On October 21, Lam Research posted fiscal first-quarter 2027 earnings of $2.20 per share on revenue of $8.22 billion, both surpassing Wall Street estimates.

CEO Tim Archer attributed the record performance to strong demand driven by artificial intelligence. However, investor sentiment soured after CFO Doug Bettinger acknowledged that the December-quarter revenue guidance of $8.6 billion "would have been a bit higher if not for some near-term supply chain constraints," triggering a sell-off across the semiconductor equipment sector.

Analysts See Temporary Headwind

Wall Street analysts appear to view the supply constraints as a short-term issue, a sentiment that is helping fuel today's rebound. Key analyst actions include:

Ad

• Wall Street Zen: Upgraded LRCX from "hold" to "buy."
• Bank of America: Reaffirmed its "buy" rating.
• Morgan Stanley: Maintained its "overweight" stance.

This consensus suggests that the analyst community believes the company's fundamental growth drivers remain intact despite the near-term operational challenges.

Broader Market Lifts Tech Sector

A constructive backdrop in the wider market is also providing a tailwind for Lam Research and other technology stocks. The S&P 500 and Nasdaq Composite were both up approximately 0.4% as investors position for a heavy week of earnings from tech giants and the Federal Reserve's upcoming policy decision.

Today's bounce comes after a significant downturn for the stock, which had declined nearly 25% over the past month. The combination of oversold technical conditions, resilient fundamentals, and renewed analyst support is contributing to the recovery, though the shares are still well off their 52-week high of $438.50.